The TSIII SOI implant is a groundbreaking advancement in the field of dental implantology, boasting unprecedented blood coagulation capability and excellent osseointegration characteristics. These recent achievements in biocompatibility improve the entire patient experience and support aesthetic and functional restoration.

Nearly a decade ago, Osstem’s researchers developed the pioneering SOI technology for a surface treatment that significantly improves osseointegration. The SOI treatment prevents the formation of biofilm and rapidly forms ample blood clots on the implant surface to activate a fibrin network, resulting in higher bone attachment compared with other implant surface treatments.

These advanced features are achieved by utilising UV and the HEPES buffering agent in treating the surface of TSIII SOI implants during production. UV treatment modifies the physiochemical characteristics of titanium, improving the implants’ biological activity by removing deposited hydrocarbons and restoring surface hydrophilicity. The HEPES coating also preserves this hydrophilicity by preventing the formation of hydrocarbons, and it establishes a neutral physiological pH level that inhibits osteoclasts and supports osteoblasts. Together, the UV and HEPES treatments produce a super-hydrophilic implant coating which accelerates the osseointegration and healing process.

Since the SOI surface launch in 2021, it has been widely adopted by dentists in Europe. It shortens the implant osseointegration period from a maximum of six months down to two months.